Thursday, April 1, 2021
8 am PDT, 11 am EDT, 17:00 CET
Andrew Bradbury, MD, PhD, Chief Scientific Officer at Specifica
Noah T. Ditto, Technical Product Manager at Carterra
- Rapidly characterize large panels of antibodies for kinetics, affinity, and epitope diversity.
- Obtain high quality data directly from crude supernatants.
- Accelerate library-to-lead triage.
- Build your IP portfolio.
During the COVID-19 pandemic, new technologies have enabled the biopharmaceutical industry to develop therapeutic antibodies fast. The Carterra LSA provides researchers with the screening and characterization throughput and functionality needed to match the output from today’s state-of-the-art antibody expression platforms. This enables all antibodies to be rapidly and comprehensively screened early in the discovery process so that unique epitopes and potential novel therapeutic candidates can be identified.
Andrew Bradbury PhD, Chief Scientific Officer of Specifica, will discuss their next-generation antibody library platform that provides robust antibody diversity and delivers superior therapeutics. Andrew discusses how Carterra’s high throughput kinetics and epitope binning technologies enable the rapid discovery of SARS-CoV-2 neutralizing antibodies.
Noah T. Ditto, Technical Product Manager at Carterra will discuss how high throughput Surface Plasmon Resonance (HT-SPR) facilitates a paradigm shift in antibody screening and characterization—now discover therapeutic candidates in days vs. months.